NIH halts enrollment in trial for SIGA’s mpox antiviral after disappointing datanews2024-12-11T18:18:08+00:00December 11th, 2024|Endpoints News|
Candel soars on prostate cancer data despite unclear prospectsnews2024-12-11T18:04:23+00:00December 11th, 2024|Endpoints News|
Relay Therapeutics plans pivotal trial in second-line breast cancer for 2025news2024-12-11T16:00:26+00:00December 11th, 2024|Endpoints News|
#ASH24: Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapiesnews2024-12-11T15:00:39+00:00December 11th, 2024|Endpoints News|
Acelyrin says goodbye to the drug that got it a $540M IPO in 2023news2024-12-11T14:51:40+00:00December 11th, 2024|Endpoints News|
#SABCS24: Lilly’s oral SERD makes strides in breast cancer with Phase 3 datanews2024-12-11T13:15:04+00:00December 11th, 2024|Endpoints News|
Q32 Bio’s stock crashes after atopic dermatitis fail, alopecia trial snafunews2024-12-11T12:00:58+00:00December 11th, 2024|Endpoints News|
The Endpoints 100 Survey: Biotech industry braces for Trump 2.0news2024-12-11T12:00:55+00:00December 11th, 2024|Endpoints News|
Bayer exits Europe pact with Moberg for nail fungus drug after Phase 3 failnews2024-12-11T11:53:46+00:00December 11th, 2024|Endpoints News|
#ASH24: Early data on BTK degraders suggest promise of next-gen approachnews2024-12-10T20:44:46+00:00December 10th, 2024|Endpoints News|
